Objectives: The dermato-oncology unit in the Hôpital SAINT LOUIS will be a clinical partner of the IMMOMEC therapy trial in metastatic Merkel cell carcinoma, actively participating in patient recruitment and treatment, as well as collecting biological samples for biobanking.
Expertise relevant to the proposed work: Celeste Lebbé is professor of dermatology in Saint-Louis Hospital in Paris, and currently head of the skin cancer unit in the Department of Dermatology. She has particular interest in the field of soft tissue sarcoma, melanoma and cancer in immunosuppressed patients. She has expertise both in terms of clinical and biological research in virus-induced cancers, and has been investigator for more than 15 years in clinical trials in the field of dermato-oncology. She currently conducts biological research in the development of new melanoma models, on the role of EMMPRIN and cKIT in melanoma development and progression, together with N. Dumaz (U976), S. Mourah (U976) and A. Janin (Department of Pathology, Hopital Saint-Louis). In the field of soft tissue sarcoma, she is particularly interested in the role of HHV-8 in Kaposi’s sarcoma pathogenesis and developing targeted therapies for Kaposi’s sarcoma and dermatofibrosarcoma. The dermato-oncology unit in the Dermatology Department of Saint Louis Hospital has an important recruitment of patients suffering from skin cancer (melanoma >150/y, sarcoma >60 /y, lymphoma 70/y, advanced squameous cell carcinoma 40/y, Merkel cell carcinoma 15 to 20/y). The center has specialized facilities for performing clinical trials in collaboration with a dedicated clinical trial center which has expertise even in early-phase trials. The center has developed strong collaborations with the Departments of Plastic Surgery, Radiology and Nuclear Medicine, Biostatistics, and with the Dermatological Research Center (DRC) (U 976), the laboratory of Pharmacology (U976) , and the Laboratory of Pathology (U 728) in Saint–Louis Hospital.
Specific role in the project: Céleste Lebbé and Cécile Pages will be clinical investigators in the IMMOMEC clinical trial. Thus, they will be involved in WP1 and 2.